Abstract: A fitness monitor comprises a housing, a wrist band, a motion sensor, a display, a non-transitory memory element and a processing element. The wrist band is coupled to the housing and configured to attach to a wrist of a user. The motion sensor is configured to sense motion of the user and generate motion data. The display is coupled to the housing and configured to present information associated with user activity. The memory element is located in the housing and configured to store the activity data and a daily activity goal. The processing element is operably coupled to the memory element and configured to determine daily activity data, a daily activity goal corresponding to a predetermined level of activity for the user, compute an activity countdown and level of inactivity, and present, on the display, the activity countdown and inactivity indicia indicating the level of inactivity.

Abstract: The disclosure provides methods of preventing or treating ophthalmic diseases or conditions in a mammalian subject. The methods comprise administering an effective amount of an aromatic-cationic peptide to subjects in need thereof. More specifically, the disclosure provides a composition for preventing, treating, or ameliorating the symptoms of diabetic macular edema in a mammalian subject in need thereof, comprising: a therapeutically effective amount of a peptide D-Arg-2?6?-Dmt-Lys-Phe-NH2 or a pharmaceutically acceptable salt thereof.

Abstract: Cold storage unit apparatuses designed for high energy efficiency are provided, which may include: a refrigeration system; a box enclosing an interior space, the box formed by a plurality of insulated sides; an entry into the interior space including a plurality of openable barriers facilitating preventing entry of heat or moisture into the interior space; and a power system connected to the refrigeration system, the power system facilitating independent operation of the refrigeration system when not connected to a power grid, and further facilitating a net energy use of zero from a power grid when connected to a power grid. Cold storage units may further include systems for using the refrigerant of the refrigeration system to defrost one or more components of the cold storage unit, and for using the refrigerant to facilitate maintaining a desired internal temperature of the interior space of the cold storage unit.

Abstract: The present invention relates to a composition containing an extract from the Polygonum minus for cognition and cosmetic purposes. The extract of Polygonum minus includes quercetin-3-glucuronide and quercitrin. Extract of Polygonum minus is provided in an amount effective to reduce oxidative damage. A process for isolation of an active extract from Polygonum minus includes the steps of a) subjecting the Polygonum minus including aerial parts of the plant to solvent extraction preferably with a material solvent ratio of 1:10-20 by percolation at a temperature range of 70-105° C. preferably 80° C. to obtain the extract; and b) filtering the extract obtained from step (a) followed by concentration and drying involving freeze drying, spray drying or vacuum belt drying to obtain therefrom the dry extract powder.

Abstract: Activation of brown adipose tissue, treatment of obesity and/or treatment of obesity-related disorders in human or non-human animal subjects by administering to the subject a potassium channel inhibiting agent. The potassium channel inhibiting agent may comprise ShK toxin or a modified ShK toxin. Examples of modified ShK toxins include ShK-186.

Abstract: Provided herein are biocompatible scaffolds engineered to convey growth stimulatory light to cells and augment their growth on the scaffolds both in vitro and in vivo. Also provide are methods of modifying biocompatible transparent waveguides to control delivery of light from the waveguide material.

Abstract: Cold storage unit apparatuses designed for high energy efficiency are provided, which may include: a refrigeration system; a box enclosing an interior space, the box formed by a plurality of insulated sides; an entry into the interior space including a plurality of openable barriers facilitating preventing entry of heat or moisture into the interior space; and a power system connected to the refrigeration system, the power system facilitating independent operation of the refrigeration system when not connected to a power grid, and further facilitating a net energy use of zero from a power grid when connected to a power grid. Cold storage units may further include systems for using the refrigerant of the refrigeration system to defrost one or more components of the cold storage unit, and for using the refrigerant to facilitate maintaining a desired internal temperature of the interior space of the cold storage unit.

Abstract: Analogs of ShK toxin and methods for using such ShK analogs. The ShK analogs generally comprise ShK toxin attached to a chemical entity (e.g. an atom, molecule, group, residue, compound, moiety, etc.) that has an anionic charge. In some embodiments, the chemical entity attached to the ShK toxin may comprise an amino acid residue. The ShK analogs may be administered to human or non-human animal subjects to cause inhibition of potassium channels or to otherwise treat diseases or disorders. In some embodiments, the chemical entity to which the ShK toxin is attached may be chosen to provide selective inhibition of certain potassium channels (e.g., Kv1.3 channels) over other potassium channels (e.g., Kv1.1 channels). In come embodiments, the chemical entity to which the ShK toxin is attached may include a fluorophore, thereby providing a fluorophore tagged ShK analog.

Abstract: Analogs of ShK toxin and methods for using such ShK analogs. The ShK analogs generally comprise ShK toxin attached to a chemical entity (e.g. an atom, molecule, group, residue, compound, moiety, etc.) that has an anionic charge. In some embodiments the chemical entity attached to the ShK toxin may comprise an amino acid residue. The ShK analogs may be administered to human or non-human animal subjects to cause inhibition of potassium channels or to otherwise treat diseases or disorders. In some embodiments, the chemical entity to which the ShK toxin is attached may be chosen to provide selective inhibition of certain potassium channels (e.g., Kv1.3 channels) over other potassium channels (e.g., Kv1.1 channels). In come embodiments, the chemical entity to which the ShK toxin is attached may include a fluorophore, thereby providing a fluorophore tagged ShK analog.

Abstract: Activation of brown adipose tissue, treatment of obesity and/or treatment of obesity-related disorders in human or non-human animal subjects by administering to the subject a potassium channel inhibiting agent. The potassium channel inhibiting agent may comprise ShK toxin or a modified ShK toxin. Examples of modified ShK toxins include ShK-186.

Abstract: The disclosure provides methods of preventing or treating ophthalmic diseases or conditions in a mammalian subject. The methods comprise administering an effective amount of an aromatic-cationic peptide to subjects in need thereof. More specifically, the disclosure provides a composition for preventing, treating, or ameliorating the symptoms of diabetic macular edema in a mammalian subject in need thereof, comprising: a therapeutically effective amount of a peptide D-Arg-2?6?-Dmt-Lys-Phe-NH2 or a pharmaceutically acceptable salt thereof.

Abstract: A fitness monitor comprises a housing, a wrist band, a motion sensor, a display, a non-transitory memory element and a processing element. The wrist band is coupled to the housing and configured to attach to a wrist of a user. The motion sensor is configured to sense motion of the user and generate motion data. The display is coupled to the housing and configured to present information associated with user activity. The memory element is located in the housing and configured to store the activity data and a daily activity goal. The processing element is operably coupled to the memory element and configured to determine daily activity data, a daily activity goal corresponding to a predetermined level of activity for the user, compute an activity countdown and level of inactivity, and present, on the display, the activity countdown and inactivity indicia indicating the level of inactivity.

Abstract: A synthetic focal plane imaging system senses electromagnetic radiation as a distribution of energy over time rather than as a distribution of energy over space. A spatial context independent of the energy detection is developed. The synthetic focal plane imaging system includes an aperture, a mask, an electromagnetic sensor, and a computer configured to receive sample energy data and shutter modeling data from the mask to generate hyperspectral images. The synthetic focal plane imaging system incorporates a spiral rotating mask to create theta-space rotational masking architectures resulting in simple cyclical linear equations that can be processed quickly and efficiently to generate the hyperspectral images. The system captures image content at multiple wavelengths, electronically processes the resulting data as an image cube with stacked layers of images. Each layer corresponds to a particular wavelength of the imaged object with the same physical locations arranged on top of each other to form the stack.

Abstract: A fitness monitor comprises a housing, a wrist band, a motion sensor, a display, a non-transitory memory element and a processing element. The wrist band is coupled to the housing and configured to attach to a wrist of a user. The motion sensor is configured to sense motion of the user and generate motion data. The display is coupled to the housing and configured to present information associated with user activity. The memory element is located in the housing and configured to store the activity data and a daily activity goal. The processing element is operably coupled to the memory element and configured to determine daily activity data, a daily activity goal corresponding to a predetermined level of activity for the user, compute an activity countdown and level of inactivity, and present, on the display, the activity countdown and inactivity indicia indicating the level of inactivity.

Abstract: Analogs of ShK toxin and methods for using such ShK analogs. The ShK analogs generally comprise ShK toxin attached to a chemical entity (e.g. an atom, molecule, group, residue, compound, moiety, etc.) that has an anionic charge. In some embodiments the chemical entity attached to the ShK toxin may comprise an amino acid residue. The ShK analogs may be administered to human or non-human animal subjects to cause inhibition of potassium channels or to otherwise treat diseases or disorders. In some embodiments, the chemical entity to which the ShK toxin is attached may be chosen to provide selective inhibition of certain potassium channels (e.g., Kv1.3 channels) over other potassium channels (e.g., Kv1.1 channels). In come embodiments, the chemical entity to which the ShK toxin is attached may include a fluorophore, thereby providing a fluorophore tagged ShK analog.

Abstract: The present invention relates to a composition containing an extract from the Polygonum minus for cognition and cosmetic purposes. The extract of Polygonum minus includes quercetin-3-glucuronide and quercitrin. Extract of Polygonum minus is provided in an amount effective to reduce oxidative damage. A process for isolation of an active extract from Polygonum minus includes the steps of a) subjecting the Polygonum minus including aerial parts of the plant to solvent extraction preferably with a material solvent ratio of 1:10-20 by percolation at a temperature range of 70-105° C. preferably 80° C. to obtain the extract; and b) filtering the extract obtained from step (a) followed by concentration and drying involving freeze drying, spray drying or vacuum belt drying to obtain therefrom the dry extract powder.

Abstract: Cold storage unit apparatuses designed for high energy efficiency are provided, which may include: a refrigeration system; a box enclosing an interior space, the box formed by a plurality of insulated sides; an entry into the interior space including a plurality of openable barriers facilitating preventing entry of heat or moisture into the interior space; and a power system connected to the refrigeration system, the power system facilitating independent operation of the refrigeration system when not connected to a power grid, and further facilitating a net energy use of zero from a power grid when connected to a power grid. Cold storage units may further include systems for using the refrigerant of the refrigeration system to defrost one or more components of the cold storage unit, and for using the refrigerant to facilitate maintaining a desired internal temperature of the interior space of the cold storage unit.

Abstract: Analogs of ShK toxin and methods for using such ShK analogs. The ShK analogs generally comprise ShK toxin attached to a chemical entity (e.g. an atom, molecule, group, residue, compound, moiety, etc.) that has an anionic charge. The ShK analogs may be administered to human or non-human animal subjects to cause inhibition of potassium channels or to otherwise treat diseases or disorders. In some embodiments, the chemical entity to which the ShK toxin is attached may be chosen to provide selective inhibition of certain potassium channels (e.g., Kv 1.3 channels) over other potassium channels (e.g., Kv 1.1 channels). In come embodiments, the chemical entity to which the ShK toxin is attached may include a fluorophore and such fluorophore-tagged ShK analogs may be used in flow cytometry alone, or in conjunction with class II tetramers that can detect autoreactive cells.

Abstract: Activation of brown adipose tissue, treatment of obesity and/or treatment of obesity-related disorders in human or non-human animal subjects by administering to the subject a potassium channel inhibiting agent. The potassium channel inhibiting agent may comprise ShK toxin or a modified ShK toxin. Examples of modified ShK toxins include ShK-186.

Abstract: The disclosure provides methods of preventing or treating ophthalmic diseases or conditions in a mammalian subject. The methods comprise administering an effective amount of an aromatic-cationic peptide to subjects in need thereof. More specifically, the disclosure provides a composition for preventing, treating, or ameliorating the symptoms of diabetic macular edema in a mammalian subject in need thereof, comprising: a therapeutically effective amount of a peptide D-Arg-2?6?-Dmt-Lys-Phe-NH2 or a pharmaceutically acceptable salt thereof.